(Press-News.org) Doctors often ask kidney disease patients on dialysis to limit the amount of phosphate they consume in their diets, but this does not help prolong their lives, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The results even suggest that prescribing low phosphate diets may increase dialysis patients' risk of premature death.
Blood phosphate levels are often high in patients with kidney disease, and dialysis treatments cannot effectively remove all of the dietary phosphate that a person normally consumes. Because elevated phosphate can lead to serious complications and premature death, dialysis patients are advised to restrict their phosphate intake and/or take phosphate binder medications. Kidney specialists and dietitians have long espoused dietary phosphate restriction; however, there have been few studies of its long-term effects on patient survival and health.
To investigate the issue, Steven Brunelli, MD, MSCE (Brigham and Women's Hospital and Harvard Medical School), Katherine Lynch, MD (Beth Israel Deaconess Medical Center), and their colleagues analyzed data from 1751 patients on dialysis who were followed for an average of 2.3 years. Prescribed daily dietary phosphate was restricted to levels < 870 mg, 871-999 mg, 1000 mg, 1001-2000 mg, and not restricted in 300, 314, 307, 297 and 533 participants, respectively.
The researchers found that patients who were prescribed more restrictive dietary phosphate levels had poorer nutritional status and were more likely to require nutritional supplements. Also, patients with more liberal dietary phosphate restrictions were less likely to die during the study. Specifically, patients prescribed 1001-2000 mg/day were 27% less likely to die and those with no specified phosphate restriction were 29% less likely to die than patients prescribed < 870 mg/day.
When comparing different subgroups of patients, the investigators found a more pronounced survival benefit of liberal dietary phosphate prescription among non-blacks, patients without elevated phosphate levels, and those not taking vitamin D.
"Our data suggest that prescription of low phosphate diets did not improve survival among hemodialysis patients and may, in fact, be associated with greater mortality," said Dr. Brunelli. "In part, this may relate to compromised intake of other essential macronutrients—such as protein—that occur unintendedly when low phosphate diets are prescribed, which may offset or supersede any beneficial effects on phosphate mitigation."
Dr. Brunelli noted that these findings apply to naturally occurring phosphate only and do not pertain to foods that are high in phosphate due to phosphate-containing food additives, which were much less abundant in foods at the time the study data were collected (1995-2001). This is very important for several reasons: 1) phosphate additives are now exceedingly common in foods and are present in high doses, 2) additive phosphate is more readily absorbed by the body than naturally occurring phosphate, and 3) foods with intrinsically high phosphate tend to be rich in other nutrients, whereas foods rendered high in phosphate are not necessarily so. Therefore, the effects of foods that are high in phosphate-containing food additives should be investigated in future studies.
###
Study co-authors include Rebecca Lynch, MS, RD (Brigham and Women's Hospital) and Gary Curhan, MD, ScD (Brigham and Women's Hospital and Harvard Medical School).
Disclosures: Dr. Brunelli's spouse is an employee of Genzyme, which manufactures Renvela, a phosphate binder. Dr. Brunelli has served on advisory boards for Amgen and C.B. Fleet Company. Dr. Curhan is the incoming editor of CJASN. The other authors reported no financial disclosures.
The article, entitled "The Association between Prescribed Dietary Phosphate Restriction and Mortality among Hemodialysis Patients," will appear online at http://cjasn.asnjournals.org/ on December 9, 2010, doi 10.2215/CJN.04620510.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966 and comprised of more than 12,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
Researchers have long known that the devastating disease called Duchenne muscular dystrophy (DMD) is caused by a single mutation in a gene called dystrophin. The protein encoded by that gene is critical for the integrity of muscle; without it, they are easily damaged. But new findings in mice reported online in the journal Cell on December 9th by researchers at Stanford suggest that disease symptoms, including progressive muscle weakening leading to respiratory failure, only set in when skeletal muscle stem cells can no longer keep up with the needed repairs.
"This is ...
STANFORD, Calif. — For years, scientists have tried to understand why children with Duchenne muscular dystrophy experience severe muscle wasting and eventual death. After all, laboratory mice with the same mutation that causes the disease in humans display only a slight weakness. Now research by scientists at the Stanford University School of Medicine, and a new animal model of the disease they developed, points a finger squarely at the inability of human muscle stem cells to keep up with the ongoing damage caused by the disorder.
"Patients with muscular dystrophy experience ...
ROME (10 December 2010)—The Global Crop Diversity Trust today announced a major global search to systematically find, gather, catalogue, use, and save the wild relatives of wheat, rice, beans, potato, barley, lentils, chickpea, and other essential food crops, in order to help protect global food supplies against the imminent threat of climate change, and strengthen future food security.
The initiative, led by the Global Crop Diversity Trust, working in partnership with national agricultural research institutes, Royal Botanic Gardens, Kew, and the Consultative Group ...
San Antonio, Tex. -- A drug that shows promise for preventing breast cancer in postmenopausal women with an increased risk of developing the disease, appears to reduce mammographic breast density in the same group of women. Having dense breast tissue on mammogram is believed to be one of the strongest predictors of breast cancer. The preliminary analysis from the small, phase II study was presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in Texas.
The ongoing study at Georgetown Lombardi Comprehensive Cancer Center and the Center for Cancer ...
RICHLAND, Wash. -- New high resolution images of electrode wires made from materials used in rechargeable lithium ion batteries shows them contorting as they become charged with electricity. The thin, nano-sized wires writhe and fatten as lithium ions flow in during charging, according to a paper in this week's issue of the journal Science. The work suggests how rechargeable batteries eventually give out and might offer insights for building better batteries.
Battery developers know that recharging and using lithium batteries over and over damages the electrode materials, ...
Spearheaded by the University of Manchester's Jodrell Bank Observatory and funded by the Science and Technology Facilities Council, the e-MERLIN telescope will allow astronomers to address key questions relating to the origin and evolution of galaxies, stars and planets.
To demonstrate its capabilities, University of Manchester astronomers turned the new telescope array toward the "Double Quasar". This enigmatic object, first discovered by Jodrell Bank, is a famous example of Einstein's theory of gravity in action.
The new image shows how the light from a quasar billions ...
BOSTON, Mass. (December 9, 2010)—A team of researchers from Harvard Medical School, Brigham and Women's Hospital, and Massachusetts General Hospital, with others from the United States and Haiti, has determined that the strain of cholera erupting in Haiti matches bacterial samples from South Asia and not those from Latin America. The scientists conclude that the cholera bacterial strain introduced into Haiti probably came from an infected human, contaminated food or other item from outside of Latin America. It is highly unlikely, they say, that the outbreak was triggered ...
The technique, which they describe in the journal Science, involves rearranging the holes left by missing atoms to tune the properties of dopants – the chemical impurities that give the semiconductors in computer chips their special properties.
Though the technique is currently limited to the laboratory, it could prove valuable to industry in the future, as the continued miniaturization of cell phone and computer chips makes the performance of individual atoms in a semiconductor more important.
"The effect we discovered is probably already going on inside the devices ...
VIDEO:
Neurologists finally have an answer to one of the most important questions about Alzheimer's disease: In a study published in Science Express, researchers show that rising brain levels of a...
Click here for more information.
Neurologists finally have an answer to one of the most important questions about Alzheimer's disease: Do rising brain levels of a plaque-forming substance mean patients are making more of it or that they can no longer clear it from their brains ...
In Alzheimer's disease, a protein fragment called beta-amyloid accumulates at abnormally high levels in the brain. Now researchers funded by the National Institutes of Health have found that in the most common, late-onset form of Alzheimer's disease, beta-amyloid is produced in the brain at a normal rate but is not cleared, or removed from the brain, efficiently. In addition to improving the understanding of what pathways are most important in development of Alzheimer's pathology, these findings may one day lead to improved biomarker measures for early diagnosis as well ...
